MIRA PHARMACEUTICALS, INC.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
MIRA$0.62+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets
CONDENSED CONSOLIDATED BALANCE SHEETS
| June 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash | $3,609,442 | $6,346,921 |
| Prepaid expenses | 54,286 | 28,146 |
| Short-term investments – related party | 4,503,973 | 4,683,099 |
| Total current assets | 8,167,701 | 11,058,166 |
| Related party receivable | 35,439 | 35,439 |
| Total assets | $8,203,140 | $11,093,605 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Trade accounts payable and accrued liabilities | $40,823 | $129,203 |
| Accrued compensation – related party | — | 242,258 |
| Advance payable to related party | — | 330,607 |
| Total current liabilities | 40,823 | 702,068 |
| Total liabilities | 40,823 | 702,068 |
| Commitments and contingencies (Note 6) | - | - |
| Stockholders’ Equity | ||
| Preferred Stock, $0.0001 par value, 10,000,000 shares authorized and none issued or outstanding. | — | — |
| Common Stock, $0.0001 par value; 100,000,000 shares authorized, 42,022,087 and 41,938,587 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively. | 4,202 | 4,194 |
| Additional paid-in capital | 50,097,007 | 49,967,549 |
| Accumulated deficit | (41,938,892) | (39,580,206) |
| Total stockholders’ equity | 8,162,317 | 10,391,537 |
| Total liabilities and stockholders’ equity | $8,203,140 | $11,093,605 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.